Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of SHR3680 with Midazolam, Warfarin, and Omeprazole in Prostate Cancer
NCT04676035Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezvilutamide in prostate cancer (PCa), sponsored by Hengrui. Primary endpoint: Pharmacokinetics parameters of Midazolam, S-Warfarin and Omeprazole at Day 22. Started Jun 2020; status: completed.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04676035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676035.